

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 706 795 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
17.04.1996 Bulletin 1996/16

(21) Application number: **95306159.5**

(22) Date of filing: **04.09.1995**

(51) Int Cl.⁶: **A61K 31/44**, A61K 31/515,
A61K 31/235, A61K 31/445,
A61K 31/165, A61K 31/415,
A61K 31/11, A61K 31/12,
A61K 31/055

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **21.09.1994 US 310171**

(71) Applicant: **PFIZER INC.**
New York, N.Y. 10017 (US)

(72) Inventors:
• **Cohan, Victoria L.**
Groton, Connecticut 06340 (US)
• **Duplantier, Allen J.**
Ledyard, Connecticut 06339 (US)

(74) Representative: **Wood, David John et al**
PFIZER LIMITED,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Catechol diether compounds as inhibitors of TNF release**

(57) This invention relates to the use of catechol diether compounds for the manufacture of a medicament for use as an inhibitor of tumor necrosis factor (TNF). The catechol diether compounds are useful as inhibitors of TNP per se and in the treatment or alleviation of inflammatory conditions or disease, including but not limit-

ed to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexis associated with AIDS or cancer.

EP 0 706 795 A2

Description

Background of the Invention

This invention relates to a method of inhibiting production of TNF (tumor necrosis factor) in a mammal in need thereof which method comprises administering to said mammal an effective amount of a compound of the formula (I) (shown below) or a pharmaceutically acceptable salt thereof, which, as such are also useful in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, multiple sclerosis and other autoimmune diseases, graft versus host disease and cachexia associated with AIDS or cancer; and this invention also relates to pharmaceutical compositions useful therefor.


TNF is produced by monocytes/macrophages and has a variety of biological activities relevant to the pathogenesis of rheumatoid arthritis (RA) and osteoarthritis (OA). Firstly, TNF can promote the accumulation of all leukocyte types by stimulating the endothelium to express adhesion molecules (T.H. Pohlman et al., *J. Immunol.*, **136**, pp. 4548-4553, 1986) and to release secondary chemotactic cytokines such as interleukin 8 (R.M. Strieter et al., *Science*, **243**, pp. 1467-1469, 1989). Secondly, TNF can stimulate cells within the joint to synthesize and express the inducible cyclooxygenase enzyme (COX 2) and the inducible NO synthase. The products of these enzymes, prostaglandins and NO, are important mediators of pain and inflammation. Thirdly, and perhaps most importantly, TNF, like IL-1, can activate chondrocytes to degrade their own extracellular matrix and suppress synthesis of cartilage matrix components leading to cartilage destruction. In addition to these effects, TNF plays a pivotal role in the regulation of the production of other cytokines. This has been demonstrated in cultures of dissociated RA synovial cells where blocking the activity of TNF can inhibit the secretion of IL-1 (F.M. Brennan et al., *Lancet*, **2**, pp. 244-247, 1989). Thus, blocking TNF production should prevent the synthesis of other downstream cytokines such as IL-1. Finally, TNF has been immunolocalised in both RA and OA synovial membranes (M.N. Fardahi et al., *Ann. Rheum. Dis.*, **52**, pp. 870-875, 1993).

TNF is recognized to be involved in many infectious and auto-immune diseases (W. Fiers, *FEBS Letters*, 1991, **285**, p. 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., *Clinical Immunology and Immunopathology*, 1992, **62**, p. S11).

The compounds utilized in the present invention are disclosed and claimed in WO-A-94/12461 wherein said compounds are disclosed as having phosphodiesterase type IV (PDE_{IV}) inhibiting activity. The teachings thereof are incorporated herein by reference.

Summary of the Invention

This invention is concerned with a method of inhibiting production of tumor necrosis factor (TNF) in a mammal in need thereof and/or a method of treating or alleviating inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, multiple sclerosis and other autoimmune diseases, graft versus host disease and cachexia associated with AIDS or cancer which method comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I)



(I)

the racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof wherein

R¹ is selected from the group consisting of methyl, ethyl, difluoromethyl and trifluoromethyl;

R² is selected from the group consisting of (C₁-C₆)alkyl, alkoxyalkyl having 3 to 7 carbons in the alkoxy portion and 2 to 4 carbons in the alkyl portion, phenoxyalkyl having 2 to 6 carbons in the alkyl portion, (C₃-C₇)cycloalkyl, (C₆-C₉) polycycloalkyl, phenylalkyl having 1 to 8 carbons in the alkyl portion, phenylaminoalkyl having 2 to 6 carbons in the alkyl portion and the amino may be optionally substituted with (C₁-C₄) alkyl and indanyl,

where the alkyl portion of said alkyl, phenoxyalkyl, cycloalkyl, polycycloalkyl, phenylalkyl and indanyl may optionally be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,

and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄)alkyl,

(C₁-C₄)alkoxy or halogen;

A and B are independently selected from the group consisting of a covalent bond, optionally substituted (C₁-C₅)alkylene, optionally substituted (C₂-C₅)alkenyl and optionally substituted phenylene,

where said optionally substituted alkylene may be monosubstituted and each substituent is selected from the group consisting of oxo, (C₁-C₄)alkoxy, CO₂R⁶ and hydroxy,


said optionally substituted alkenyl may be monosubstituted with (C₁-C₄)alkoxy or CO₂R⁶, and

said optionally substituted phenylene may be monosubstituted with (C₁-C₄)alkoxy, CO₂R⁶ or hydroxy,

wherein R⁶ is hydrogen or (C₁-C₄)alkyl;

Y is selected from the group consisting of a covalent bond, O, NR⁶ and S wherein R⁶ is as defined above;

Z is selected from the group consisting of



where Q¹, Q², Q³, and Q⁴ are independently N, CH or, when also bonded to B, C and provided that at least two of Q¹, Q², Q³, and Q⁴ are not N;

X is selected from the group consisting of NR⁴ and S;

e is an integer from 1 to 3;

g is an integer from 1 to 4;

j is an integer from 1 to 5;

each R³ is independently selected from the group consisting of hydrogen, halogen, CF₃, (C₁-C₆)alkyl, CH(R⁷)CO₂R⁴, (C₁-C₆)alkoxy, CO₂R⁴, CONR⁴R⁵, CONHOH, CH₂NR⁴R⁵, NR⁴R⁵, nitro, hydroxy, CN, SO₃H, phenylalkyl having 1 to 4 carbons in the alkyl portion, SO₂NR⁴R⁵, N(SO₂R⁸)₂ and NHSO₂R⁸,

where R⁴ for each occurrence is independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, phenyl optionally substituted with (C₁-C₄)alkyl or halogen, CH(R⁷)CO₂R⁶, (C₃-C₇)cycloalkyl, phenylalkyl having 1 to 4 carbons in the alkyl portion and dialkylaminoalkyl having a total of 5 carbons in the dialkylamino portion and having 2 to 5 carbons in the alkyl portion where R⁶ is as defined above,

R⁵ for each occurrence is independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, phenylalkyl having 1 to 4 carbons in the alkyl portion, phenyl, pyridyl, pyrimidyl, thiazolyl and oxazolyl,

or R⁴ and R⁵ are taken together with the nitrogen to which they are attached and form an optionally substituted saturated or unsaturated 5- or 6-membered ring, a saturated or unsaturated 6-membered heterocyclic ring containing two heteroatoms, or a quinoline ring optionally substituted with fluoro,


where said optionally substituted saturated or unsaturated 5- or 6-membered ring may be mono- or di-substituted and each substituent is independently selected from the group consisting of alkyl having 1 to 4 carbons, CO₂R⁷ wherein R⁷ is as defined below, CONH₂, CON(CH₃)₂, oxo, hydroxy, NH₂ and N(CH₃)₂, and said saturated or unsaturated 6-membered heterocyclic ring containing two heteroatoms has the second heteroatom selected from the group consisting of O, S, NH, NCH₃, NCOCH₃ and NCH₂Ph;

R⁷ for each occurrence is independently selected from the group consisting of hydrogen and (C₁-C₄)alkyl;


and R⁸ is selected from the group consisting of (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, phenyl and phenylalkyl having 1 to 4 carbons in the alkyl portion;

with the proviso that:


when R¹ is methyl or ethyl; R² is (C₇-C₉)polycycloalkyl or indanyl; A, B and Y are covalent bonds; X is N; and R³ is hydrogen;
then Z is not



when the compound of formula I is



wherein X is CH or N and R² is as defined above for formula 1, the CO₂H can only be in the para position relative to the bond to the catechol moiety;
when the compound of formula I is



wherein X is CH or N and R² and R⁵ are as defined above for formula I, the amide can only be in the para or meta position; and the compound of formula I cannot be *trans*-1-[4-[2-[3-(cyclopentyloxy)-4-methoxy-phenyl]-ethenyl]phenyl]-2-methyl-1H-imidazo[4,5c]-pyridine.

This invention is further directed to a method of treating or alleviating inflammatory conditions or disease, sepsis, septic shock, tuberculosis, multiple sclerosis and other autoimmune diseases, graft versus host disease or cachexia associated with AIDS or cancer in a mammal in need thereof which method comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) as defined hereinabove. Thus in a further aspect, this invention provides a method of treating or alleviating rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis or inflammatory bowel disease, in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) as defined hereinabove.

Further still, this invention provides pharmaceutical compositions comprising a pharmaceutically acceptable diluent or carrier and a tumor necrosis factor inhibiting amount of a compound selected from the group consisting of compounds of the formula (I) as defined hereinabove.

A preferred method of inhibiting production of TNF in a mammal in need thereof comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) wherein A, Y, B and Z are as defined hereinabove for formula (I); R¹ is methyl or difluoromethyl; and R² is (C₃-C₇)cycloalkyl, (C₆-C₉)polycycloalkyl, phenylalkyl, phenoxyalkyl or indanyl,

where the alkyl portion of said alkyl, cycloalkyl, polycycloalkyl, phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,

and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄)alkyl, (C₁-C₄)alkoxy or halogen.


A more preferred method of inhibiting production of TNF in a mammal in need thereof comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) wherein Z is as defined hereinabove for formula (I); A and B are independently selected from the group consisting of a covalent bond, (C₁-C₅)alkylene, (C₂-C₅)alkenyl and phenylene; Y is a covalent bond or O; R¹ is methyl or difluoromethyl; and R² is (C₃-C₇)cycloalkyl, (C₆-C₉)polycycloalkyl, phenylalkyl, phenoxyalkyl or indanyl,

where the alkyl portion of said alkyl, cycloalkyl, polycycloalkyl, phenylalkyl, phenoxyalkyl and indanyl may optionally

be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,

and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄)alkyl, (C₁-C₄)alkoxy or halogen.

An even more preferred method of inhibiting production of TNF in a mammal in need thereof comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) wherein A is covalent bond, methylene or cis-ethenyl; B is a covalent bond or phenylene; Z is selected from the group consisting of




wherein R³, X and e are as defined hereinabove for formula (I); j is 1 or 2; Q⁴ is CH or N and Q² is CH or N; Y is a covalent bond or O; R¹ is methyl or difluoromethyl; and R² is (C₃-C₇)cycloalkyl, (C₆-C₉)polycycloalkyl, phenylalkyl, phenoxyalkyl or indanyl,

where the alkyl portion of said alkyl, cycloalkyl, polycycloalkyl, phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,


and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄)alkyl, (C₁-C₄)alkoxy or halogen.

A most preferred method of inhibiting production of TNF in a mammal in need thereof comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) wherein A is covalent bond, methylene or cis-ethenyl; B is a covalent bond or phenylene; Z is selected from the group consisting of




wherein X is as defined hereinabove for formula (I); j is 1 or 2; Q⁴ is CH or N; Q² is CH or N; R³ is (C₁-C₄)alkyl, CO₂H, CONH₂, nitro, NHSO₂Me, CF₃ or hydrogen; and e is 1; Y is a covalent bond or O; R¹ is methyl; and R² is cyclopentyl, norbornyl, indanyl, 1-phenylbut-3-yl, 1-phenoxyeth-2-yl, 1-phenylhex-5-yl or 1-phenylpent-4-yl.


A further most preferred method of inhibiting production of TNF in a mammal in need thereof comprises administering to said mammal an effective amount of a compound selected from the group consisting of compounds of the formula (I) wherein Z is selected from the group consisting of




wherein R³ is H, CO₂H or CONH₂ and X is as defined hereinabove for formula (I),



wherein R^3 is (C_1-C_6) alkyl and Q^2 is CH or N,



wherein R^3 is H, CO_2H or $CONH_2$, and




wherein R^3 is (C_1-C_6) alkyl, H, CO_2H , $CONH_2$, CF_3 , NO_2 or $NHSO_2Me$ and j is 1 or 2; A is a covalent bond, methylene or cis-ethenyl; B is a covalent bond or phenylene; Y is a covalent bond or O; R^1 is methyl; and R^2 is cyclopentyl, norbornyl, indanyl, 1-phenylbut-3-yl, 1-phenoxyeth-2-yl, 1-phenylhex-5-yl or 1-phenylpent-4-yl.

As used throughout this specification and the appendant claims, the terms "alkyl" and "alkoxy" include both straight chain and branched groups; the term "halogen" includes fluoro, chloro and bromo; and the symbol "Ph" in the term "NCH₂Ph" means phenyl.

Those members of the substituent Z which are bicyclic are attached to the remainder of the compound of formula (I) through the ring of the Z substituent in which the bond is drawn.

As will be readily apparent to one skilled in the art, when Z is




and one or more of Q^1 , Q^2 , Q^3 and Q^4 is N. Z cannot be bonded through one of its ring nitrogen atoms to the rest of the molecule.

Detailed Description of the Invention

The compounds utilized in the methods of the present invention having the formula (I) which comprise the racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof, are readily and generally prepared by the following reaction processes.


(a) In one process certain compounds of the formula (IV) can be prepared by the Wittig synthesis, according to the following reaction scheme:



wherein R^1 , R^2 , R^3 and j are as defined above for formula (I).

In a typical procedure, approximately one equivalent of the phenylphosphonium bromide (III), dissolved or suspended in dry THF, is treated with about 1.1 equivalents of 2.5M *n*-BuLi in hexane. This mixture is allowed to stir at about -78°C for about one hour. Then approximately one equivalent of the aldehyde (II), dissolved in anhydrous THF, is added to the formed ylide solution at about -78°C . After about one hour of stirring at about -78°C , the reaction mixture is allowed to warm to room temperature over about 18 hours. The reaction is worked-up by pouring it into water and extracting twice with a solvent such as ethyl acetate. The ethyl acetate is evaporated and the crude product is chromatographed on silica gel using 15% ether/hexanes as the eluant to yield the desired compound (IV). Both the *cis* and *trans* isomers of (IV) are isolated.


(b) In a further process, certain compounds of general formula (IX) can be prepared by a Mitsunobu type reaction, according to the following general reaction scheme:



wherein R^1 , R^2 , R^3 and j are as defined above for formula (I).

In a typical procedure, about 1 to 5 equivalents, typically 1.2 equivalents, of diisopropylazodicarboxylate (DIAD) or diethylazodicarboxylate (DEAD) is added to a mixture of about one equivalent of the alcohol (V), about one equivalent of the phenol (VIII) and about 1.1 equivalents of triphenylphosphine (TPP). All of the reactants are dissolved in a dry solvent, such as tetrahydrofuran. The reaction is stirred at room temperature for about 6 to hours, typically 18 hours. The solvent is evaporated and the crude oil is purified by column chromatography on silica gel to yield the compound of formula (IX).


(c) Certain compounds of the formula (XVI) may be synthesized according to the scheme shown below:



wherein R^1 , R^2 , R^3 and b are as defined above for formula (I).

In a typical procedure, a ketone of the formula (XV) is heated with glyoxylic acid monohydrate at about 100°C to 150°C , preferably about 120°C . The reaction is cooled to about 60°C and about 2 ml of H_2O is added. About 20 to 30 drops of concentrated NH_4OH and about 1 equivalent of hydrazine monohydrate are added. The mixture is then heated at reflux for about 2 hours. It is cooled to room temperature and about 5 ml of water is added. The mixture is stirred for about 50 to 72 hours, preferably for about 60 hours. The suspension is filtered and purified by column chromatography on silica gel followed by crystallization.


(d) Certain compounds of formula (XIX) are prepared by palladium cross coupling according to the following scheme: wherein R^1 , R^2 , R^3 and j are as defined




above for formula (I).

10 A typical procedure is carried out by taking a solution of about one equivalent of the appropriate bromo compound (XVII), dissolved in dry THF, and cooling it to about -78°C . About 1.1 equivalents of a 2.5M solution of n-BuLi is added to the bromo compound and stirred for about 40 minutes at about -78°C . About 1.2 equivalents of a 1.0M solution of ZnCl_2 in ether is added and the reaction mixture allowed to warm to room temperature over about 35 minutes. A catalytic amount, about 0.05 equivalents, of tetrakis(triphenylphosphine)palladium(0) and the required halo compound (XVIII), wherein "Halo" is I, Br or Cl but preferably I or Br, are added to the reaction mixture and allowed to stir for about 12 hours. The reaction is concentrated and chromatographed on silica gel to yield the desired compound of formula (XIX).

20 (e) Certain compounds of formula (I) may also be synthesized by reaction of bromo compounds (XVII) with amino compounds (XXII), according to the general reaction scheme:




30 wherein R^1 and R^2 are as defined above for formula (I) and




50 wherein Q^1 , Q^2 , Q^3 , Q^4 , R^3 , b and e are as defined above for formula (I).

In a typical procedure, a mixture of about one equivalent of all of the reagents shown in the above scheme are heated to about $110-150^\circ\text{C}$ for about 24 hours. The mixture is cooled to room temperature and worked-up according to standard methods well known to those skilled in the art. Chromatography on silica gel yields the desired compound of general formula (XXIII).

55 (f) The following procedure is employed to synthesize compounds of the formula




10 wherein R¹ and R² are as defined above for formula (I).
About one equivalent of an aldehyde of the formula




20 is mixed with about one equivalent of an optionally substituted 2-mercaptoaniline and heated on a steam bath for about 15 minutes. The reaction mixture is cooled and dissolved in a methanol solution of 10% FeCl₃ and stirred overnight. The reaction is diluted with H₂O and extracted with chloroform. The chloroform is evaporated and the residue is chromatographed to yield the desired benzothiazole derivatives of formula (XXIV).

25 (g) The following procedure is used to synthesize compounds of the formula




35 wherein R¹, R² and R³ are as defined above for formula (I).
About one equivalent of a compound of the formula




45 is mixed with ethyl formate and approximately 25 ml of formic acid and heated at about 100°C for about 18 hours. The solvent is evaporated and the residue chromatographed on silica gel to yield the desired benzimidazole derivatives of formula (XXV).

50 (h) Compounds having the general formula




wherein R^1 , R^2 , Q^1 , Q^2 , Q^3 and Q^4 are as defined above for formula (I), are synthesized by the following general method. A compound of the general formula




is mixed with $POCl_3$ and heated at reflux for about 24 hours. Excess $POCl_3$ is evaporated and the crude product is purified by chromatography on silica gel to yield the desired oxazolo derivatives of formula (XXVII).

(i) Compounds having the general formula




wherein R^1 , R^2 and R^3 are as defined above for formula (I), are synthesized by the following general method. A compound of the general formula (II) is mixed with an appropriate compound of the general formula




and the mixture heated to about $120^\circ C$ for about 1 to 6 hours. The resulting residue is chromatographed on silica gel to yield the desired derivative of formula (XXXI).

(j) Compounds having the general formula



wherein R^1 and R^2 are as defined above for formula (I), are synthesized by one of the two general methods described below. The first general method is a Mitsunobu type reaction illustrated by the general scheme



15 The reaction is carried out analogously to the description provided in general method (e) above.

The second general method is carried out according to the following general scheme:



wherein "Halo" is Cl, Br or I

20 A compound of general formula (XXXIV) is dissolved in anhydrous DMSO. To this mixture approximately 2.5 equivalents of anhydrous K₂CO₃ and the appropriate halide (Halo-R²) are added. The reaction mixture is heated to about 80°C for about 2-5 hours. After conventional work-up of the reaction mixture, the desired product is isolated by chromatography on silica gel.

25 As ascertained by one skilled in the art enabled by this disclosure, pharmaceutically-acceptable acid addition salts of certain compounds utilized in the present invention can be prepared which include, but are not limited to, those formed with HCl, HBr, HNO₃, H₂SO₄, H₃PO₄, CH₃SO₃H, p-CH₃C₆H₄SO₃H, CH₃CO₂H, gluconic acid, tartaric acid, maleic acid and succinic acid.

The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit TNF and, consequently, demonstrate their effectiveness for treating inflammatory conditions and diseases is shown by the following *in vitro* assay.

Lipopolysaccharide (LPS)-induced TNF Release From Human Monocytes Human Peripheral Blood Monocytes:

35 Venous blood from healthy volunteers is collected in 25 mM EDTA. Monocytes are separated by ficoll-hypaque and washed three times in complete HBSS (Hanks Balanced Salt Solution, available from GIBCO, Grand Island, NY). Cells are resuspended in a final concentration of 1.3 x 10⁶ cells per mL in pre-warmed RPMI (available from GIBCO, Grand Island, NY) (containing 5% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin/streptomycin antibiotic and 0.25 g/ml nystatin (all available from GIBCO, Grand Island, NY)). Monocytes (1 mL/well) are allowed to adhere to a 24-well Primaria Plate (coated tissue culture plates, available from VWR Scientific, South Plainfield, NJ) for 2 hours (37°C, 5% CO₂), after which time non-adherent cells are removed by gentle washing with RPMI.

Incubation:

40 Compounds are dissolved in DMSO. Each compound is tested at 4 concentrations. Fresh media (HBSS) (1.0 mL) and compound (10 µL) or DMSO control is added to each well. After 1 hour at 37°C, LPS (10 ng/mL final concentration) is added to appropriate wells. Plates are incubated overnight at 37°C. At the end of the incubation period, 250 µL of each culture supernatant is removed and duplicate 10 µL samples are tested at a 1:20 dilution for TNF activity by ELISA (available from Quantikine, R&D Operations, Minneapolis, MN) according to the manufacturer's instructions.

45 TNF is determined by interpolating the average absorbance onto a standard curve. Percent inhibition is determined by the following equation: (1 - [pg/mL TNF experimental/pg/mL TNF DMSO control]) x 100. IC₅₀ is determined by linear regression of drug concentration plotted against inhibition and interpolation of the x value at y=50 using Biostat Linear Regression Program (available from Digital, Inc., Boston, MA).

50 For administration to humans to inhibit TNF in the treatment or alleviation of inflammatory conditions or disease, including but not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer, oral dosages of the compounds are generally in the range of from 0.1-500 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 0.1 to 50 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Tablets or capsules can be given in multiple dosages to meet the dosage requirement. Dosages for intravenous administration are


typically within the range of 0.1 to 10 mg per single dose as required. For intranasal or inhaler administration, the dosage is generally formulated as a 0.1 to 1% (w/v) solution. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and all such dosages are within the scope of this invention.

For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in an admixture with a pharmaceutical diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovals either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. They may be injected parenterally; for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances; for example, enough salts or glucose to make the solution isotonic. For topical administration, they are best used in the form of solutions, lotions, ointments, salves and the like.

The following examples illustrate the synthesis of certain compounds used in the present invention. The following examples combined with the synthetic methodologies described immediately above enable those skilled in the art to make the compounds used in the present invention.

EXAMPLES 1 and 2

Reaction of the appropriate aldehyde with 2-mercapto-3-aminopyridine, analogous to the following procedure yielded the following compounds. A mixture of (2 mmols) of an appropriate aldehyde and (2.1 mmols) 2-mercapto-3-aminopyridine hydrochloride was heated on a steam bath for about 15 minutes. The resulting thick orange oil was cooled and dissolved in 5 ml of 10% FeCl₃ in methanol and allowed to stir overnight. The reaction was diluted with water and extracted with CH₂Cl₂. The CH₂Cl₂ layer was dried and evaporated to give a crude product which was purified on silica gel with CH₂Cl₂ to give the desired product. Recrystallization was performed to further purify the desired product.



Ex.#	R ²	M.P. °C	Analysis					
			Calculated %			Found %		
			C	H	N	C	H	N
1		118-120°	66.23	5.56	8.58	66.41	5.71	8.42
2		110-111°	--	--	--	--	--	--

EXAMPLE 3

6-[3-(Bicyclo[2.2.1]hept-2-yloxy)-4-methoxyphenyl]-3(2H)-pyridazinone

A mixture of 3-Exo-(±)-norbornyloxy-4-methoxyacetophenone (0.88 g, 3.38 mmol, 1.0 eq) and (0.30 g, 3.29 mmol, 0.95 eq) glyoxylic acid monohydrate was heated to about 120°C for about 2.2 hours. The light yellow melt was cooled to about 60°C and 2.0 ml of H₂O was added. Dissolution was brought on by addition of 25 drops of concentrated NH₄OH.


Hydrazine monohydrate (0.163 g, 3.29 mmol, 0.95 eq) was added and the reaction mixture heated to reflux for about 2 hours. The reaction mixture was cooled to room temperature, 5 ml of H₂O was added to it, and the mixture stirred for about 60 hours at room temperature. The resulting suspension was filtered, washed with H₂O and air dried to yield 0.87 g of a creamy yellow solid. Silica gel chromatography eluting with 5% CH₃OH-CH₂Cl₂, followed by recrystallization from isopropanol-hexane gave 0.50 g, 49%, of off-white crystals. M.P.: 188-189°C. Elemental Analysis Calc'd for C₁₈H₂₀N₂O₃:
 Calc'd: C, 69.21; H, 6.45; N, 8.95. Found: C, 68.92; H, 6.42; N, 8.88.

EXAMPLE 4**1-[3-(Cyclopentyloxy)4-methoxy-phenyl]-1H-imidazo[4,5-c]pyridine**






A solution of 2.05g of 1-(3-hydroxy-4-methoxyphenyl)-1H-imidazo[4,5-c]pyridine, 2.5 g of cyclopentylbromide and 665 mg of NaH in 20 ml of DMF was stirred at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate, dried to give 1.4 g of crude product. Recrystallization from CH₂Cl₂ gave 574 mg product. M.P.: 66-68°C.

EXAMPLE 5**Tetrahydro-5-[3-(4-phenylbutoxy)4-methoxyphenyl]-2(1H)-pyrimidinone**

Diisopropylazodicarboxylate (1.1 ml, 5.70 mmol, 1.2 eq) was added to a mixture of (1.06 g, 4.75 mmol, 1.0 eq) tetrahydro-5-(3-hydroxy-4-methoxyphenyl)-2(1H)-pyrimidinone, (1.37 g, 5.23 mmol, 1.1 eq) triphenylphosphine, and (714 mg, 4.75 mmol, 1.0 eq) 4-phenyl-1-butanol in 20 ml of anhydrous tetrahydrofuran. After heating to reflux for about 18 hours, the reaction mixture was cooled to room temperature, diluted with 350 ml ethyl acetate washed twice with 1N NaOH, once with H₂O, once with brine, dried over Na₂SO₄, and concentrated to yield an orange solid. Silica gel chromatography eluting with 4% CH₃OH-CH₂Cl₂ yielded 527 mg of a white solid, which was recrystallized from ethyl acetate to afford 480 mg, 29%, of white needles. M.P.: 142-143°C. Elemental Analysis Calc'd for C₂₁H₂₆N₂O₃: Calc'd: C, 71.17; H, 7.40; N, 7.90. Found: C, 71.12; H, 7.32; N, 7.75.


EXAMPLES 6-10







Reaction of 2(1H)-pyrimidine, tetrahydro-5-(3-hydroxy-4-methoxyphenyl)-with the appropriate alcohol of the general formula R-OH, analogous to the procedure of Example 5, yielded the following compounds:



Ex.#	R ²	M.P. °C	Analysis					
			Calculated (%)			Found (%)		
			C	H	N	C	H	N
6		157-60°	69.01	7.13	6.19	67.58	6.76	6.33
7		152-4°	71.17	7.40	7.90	71.13	7.42	7.80
8		99-101°	--	--	--	--	--	--
9		147-9°	--	--	--	--	--	--
10		90-2°	72.22	7.91	7.32	72.20	7.79	7.27

EXAMPLES 11-14

Reaction of the appropriate bromocatechol with the proper halo aromatic ester of the formula X-Ar-CO-OR⁴ followed by hydrolysis analogous to the following procedure yielded the desired products. To a solution of 1.0 eq an appropriate bromocatechol in 30 ml of dry THF at about -78°C was added 1.1 eq 2.5M n-BuLi. After stirring for about 15 minutes at about -78°C, 1.2 eq of 1.0M ZnCl₂ in ether was added and the mixture allowed to warm to room temperature over about 35 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.05 eq) and 1.0 eq of a halo aromatic ester of the formula X-Ar-CO-OR⁴ were added to the reaction and the mixture allowed to stir at room temperature for about 2.5 hours. The reaction mixture was concentrated in vacuo, costripped with CHCl₃, and chromatographed on a silica gel column eluting with ethyl acetate-hexane (0-10%). Hydrolysis of the ester was accomplished as follows. A mixture of 1.0 eq the ester in 8 ml methanol and 2.0 eq of 1N NaOH was heated to reflux for about 1.5 hours. The reaction mixture was cooled to room temperature, concentrated in vacuo, poured into 100 ml H₂O, basified to pH 12, and washed once with ethyl acetate. The aqueous layer was acidified to pH 4 and extracted three times with ethyl acetate. The ethyl acetate extracts were combined, washed once with H₂O, once with brine, dried over Na₂SO₄, and concentrated to yield the following compounds of the general formula:



Ex. #	R ²	ArCO ₂ H	M.P. °C	Analysis					
				Calculated %			Found %		
				C	H	N	C	H	N
11			221-3°	70.78	6.24	4.13	70.60	6.08	4.02
12			230-32°	73.05	6.47	--	73.16	6.51	--
13			234-6°	74.53	6.55	--	74.49	6.24	--

Ex.#	R ²	ArCO ₂ H	M.P. °C	Analysis					
				Calculated %			Found %		
				C	H	N	C	H	N
14			242-4°	77.30	6.23	--	77.28	6.25	--

EXAMPLE 152-[(4-Methoxy-4'-nitro[1,1'-biphenyl]-3-yl)oxy]bicyclo[2.2.1]heptane

To a stirred solution of (2 g, 6.73 mmol, 1.0 eq) (\pm)-1-methoxy-2-exo-norbornyloxy-4-bromobenzene in 50 ml of dry THF at about -78°C was added 2.96 ml (7.40 mmol, 1.1 eq) 2.5M n-BuLi. After about 45 minutes at about -78°C, (8.07 ml, 8.07 mmol, 1.2 eq) 1.0M ZnCl₂ in ether was added and the reaction mixture allowed to warm to room temperature over about 30 minutes. Pd(PPh₃)₄ (389 mg, 0.34 mmol, 0.05 eq) and then (1.67 g, 6.73 mmol, 1.0 eq) 1-nitro-4-iodobenzene were added and the reaction mixture stirred for about 30 minutes at room temperature. The mixture was concentrated in vacuo and chromatographed on silica gel, eluting with ethyl acetate/hexane (0-8%) to afford 1.32 g, 58%, of a yellow solid. M.P.: 134-135°C.

EXAMPLE 16N-(3'-Bicyclo[2.2.1]hept-2-yloxy)-4'-methoxy-[1,1'-biphenyl]-4-ylmethanesulfonamide

To a stirred solution of (525 mg, 1.70 mmol, 1.0 eq) 3'-(bicyclo[2.2.1]hept-2-yloxy)-4'-methoxy[1,1'-biphenyl]-4-amino in 10 ml dry CH₂Cl₂ at about 0°C was added 0.28 ml of triethylamine (2.03 mmol, 1.2 eq), followed by 355 mg (2.03 mmol, 1.2 eq) methanesulfonic anhydride. The mixture was stirred at about 0°C for about 10 minutes, then at room temperature for about 1 hour, at which point an additional 200 mg (1.1 mmol, 0.7 eq) of methane sulfonic anhydride was added. After stirring an additional 30 minutes at room temperature, the reaction mixture was concentrated in vacuo, co-distilled twice with CHCl₃, and chromatographed on silica gel eluting with ethyl acetate-hexane (10-35%) to yield 700 mg of compound. Recrystallization from ethyl acetate/hexane afforded 650 mg, 98%, of crystals. M.P.: 151-153°C. Elemental Analysis Calc'd for C₂₁H₂₅NO₄S: Calc'd: C, 65.08; H, 6.51; N, 3.61. Found: C, 64.92; H, 6.21; N, 3.53.

EXAMPLE 172-[3-[2-indoxy]-4-methoxyphenyl]-1H-imidazo[4,5-b]pyridine

To a magnetically stirred solution of 3-(2-indoxy)-4-methoxybenzaldehyde (3.0 g, 11.2 mmoles) in acetone (50 ml) was added 7 ml of 2.67 M solution of Cr₂O₃ in 50% aqueous H₂SO₄. This was exothermic enough to effect a mild reflux of acetone, and no external cooling was necessary. After stirring overnight at ambient temperature, 50 ml of H₂O was added, and the acetone was allowed to evaporate over a steam bath. The crude product was filtered and washed with 1 N HCl followed by water. Recrystallization from isopropyl ether gave 1.9 g of 3-(2-indoxy)-4-methoxybenzoic acid as off-white crystals. M.P.: 189-191°C.

A solution of 0.50 g of 3-(2-indoxy)-4-methoxybenzoic acid in 10 ml of thionyl chloride was heated at reflux for about 1 hour. Removal of the volatiles under reduced pressure gave 3-(2-indoxy)-4-methoxybenzoyl chloride as a dull pink solid which was immediately used in the next step without purification.

To a magnetically stirred solution of 2,3-diaminopyridine (1.8 mmole) in dry pyridine (15 ml) at about 0°C was added dropwise a solution of 3-(2-indoxy)-4-methoxybenzoyl chloride in dry THF (10 ml). After about 1 hour the mixture was warmed to ambient temperature and after about 16 hours the volatiles were removed under reduced pressure. The residue was suspended in 25 ml of water, filtered, and washed with water to give 0.59 g of a white solid. M.P.: 226-228°C (dec).

The above amide was suspended in 10 ml of phosphorous oxychloride and heated at reflux for about 1.5 hours, at which time the reaction mixture was homogeneous. The volatiles were removed under reduced pressure, and the residue was suspended in 25 ml of saturated sodium bicarbonate, filtered, and air-dried. Column chromatography followed by recrystallization from ethanol gave 180 mg of off-white crystals. M.P.: 206-208°C. Elemental analysis calculated for C₂₂H₁₉O₂N₃: C, 73.93; H, 5.36; N, 11.76. Found: C, 73.01; H, 5.06; N, 11.76.

EXAMPLES 18-19

Reaction of the appropriate carboxylic acid with the proper amine of the general formula NR₁R₂, analogous to the following procedure yielded the desired compounds. A suspension of an appropriate carboxylic acid (1.38 mmoles) in dry methylene chloride was treated with excess thionyl chloride (6.93 mmoles) and a catalytic amount of anhydrous DMF (3-5 drops). The resulting clear solution was heated to reflux under nitrogen atmosphere for about 1 hour. The methylene chloride was removed in vacuo and the resulting solid residue azeotroped with an additional 15 ml of dry methylene chloride. The residue was dissolved in 15 ml of dry CH₂Cl₂, cooled to about 0°C (ice bath) and dry anhydrous ammonia gas bubbled directly into the reaction mixture for approximately 5 minutes. This was followed by allowing the

EP 0 706 795 A2

reaction to stir at about 0°C for an additional hour, after which time the reaction mixture was diluted with 500 ml of ethyl acetate and 300 ml of H₂O. The organic layer was separated and washed with 1N HCl (2 x 350 ml), 2N NaOH (2 x 350 ml), water (1 x 300 ml), brine, dried over MgSO₄ and evaporated under reduced pressure which yielded the following compounds:

5

10

15

20

25

30


35

40

45

50

55




Ex.#	R ²	R ⁴	R ⁶	Position of Amide	M.P. °C	Analysis					
						Calculated %			Found %		
						C	H	N	C	H	N
18		H	H	Meta	151-153°	74.75	6.87	4.15	74.47	6.97	4.00
19		H	H	Para	245-247°	--	--	--	--	--	--

EXAMPLE 20cis-1-[4-[2-[3-(Cyclopentyloxy)-4-methoxyphenyl]-ethenylphenyl]-2-methyl-1H-imidazo[4,5-c]pyridine

5 To a stirred suspension of (1.74 g, 3.13 mmol, 1.2 eq) [[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]triphenylphosphonium bromide in 20 ml dry tetrahydrofuran at about -50°C was added (1.1 ml, 2.78 mmol, 1.1 eq) of 2.5M n-BuLi. The mixture was warmed to about 0°C over about 1 hour, cooled to about -78°C, and a solution of (600 mg, 2.53 mmol, 1.0 eq) 4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)benzaldehyde in 20 ml dry tetrahydrofuran was added dropwise over
10 about 10 minutes. The reaction mixture was allowed to warm to room temperature over about 18 hours then was quenched with 10 ml saturated NH₄Cl solution. The mixture was poured into 200 ml of H₂O and extracted twice with ethyl acetate. The ethyl acetate extracts were combined, washed once with H₂O, once with brine, dried over MgSO₄, and concentrated to give 2 g of an oil. Flash chromatography eluting with 65% acetone-hexane gave 403 mg of crude product, which was recrystallized from ether-hexane to yield 305 mg, 36%, of the cis product. The cis-product M.P.: 123-125°C. Elemental Analysis of the cis-product: Calc'd for C₂₇H₂₇N₃O₂: Calc'd: C, 76.21; H, 6.40; N, 9.87. Found: C,
15 76.14; H, 6.34; N, 9.71.










EXAMPLES 21-31







Additional examples, which were prepared according to the methods described and readily apparent to those skilled
20 in the art, are shown in the following table.



*C.B.= Covalent Bond

Ex. #	R¹	R²	A	Y	B	Z-R³	M.P.(°C)
21	CH₃		C.B.	C.B.	C.B.		244-247
22	CH₃		C.B.	C.B.	C.B.		127-128
23	CH₃		C.B.	C.B.	C.B.		169-171
24	CH₃		C.B.	C.B.	C.B.		88-90

Ex. #	R ¹	R ²	A	Y	B	Z-R ³	M.P.(°C)
25	CH ₃		C.B.	C.B.	C.B.		79-81
26	CH ₃		-CH ₂ -	-O-			129-131
27	CH ₃		C.B.	C.B.	C.B.		118-119
28	CH ₃		C.B.	C.B.	C.B.		185-187


Ex. #	R ¹	R ²	A	Y	B	Z-R ³	M.P.(°C)
29	CH ₃		C.B.	C.B.	C.B.		221-223
30	CH ₃		C.B.	C.B.	C.B.		131-133
31	CH ₃		C.B.	C.B.	C.B.		153-154

Preparation 13-(Bicyclo[2.2.1]hept-2-yloxy)-4-methoxybenzaldehyde

Diisopropylazodicarboxylate (7.8 ml, 39.5 mmol, 1.2 eq) was added neat to a 25° solution of (5.00 g, 32.9 mmol, 1.0 eq) 3-hydroxy-4-methoxybenzaldehyde (9.48 g, 36.1 mmol, 1.1 eq) triphenylphosphine, and (3.69 g, 32.9 mmol, 1.0 eq) (±)-endo-norborneol in 100 ml of anhydrous tetrahydrofuran. After refluxing for 6 hours, the reaction mixture was poured into 1 liter of H₂O and extracted twice with ethyl acetate. The ethyl acetate layers were combined and washed twice with H₂O, once with 1N NaOH, once with H₂O and once with brine and then the solution was dried over anhydrous sodium sulfate. Filtration, concentration, and drying afforded 26.1 g of crude product, which was chromatographed on a silica gel column, eluting with 20% ethyl acetate-hexane to afford 5.68 g, 70% yield, of a yellow oil. IR(cm⁻¹): 1680, 1580. NMR (CDCl₃): δ 9.82 (s, 1H), δ 4.27 (d, 1H). High resolution mass spectra (HRMS): 246.1300.

PREPARATIONS 2-8

Reaction of the appropriate vanillin with the requisite alcohol of the formula R²-OH, analogous to the procedure of Preparation 1, afforded the following compounds:



Prep.#	R ¹	R	R ²	M.P. °C	M.W.	Mass Spec (M+)	Analysis			
							Calculated (%)		Found (%)	
							C	H	C	H
2	CH ₃	-CHO		oil	220.3	220	--	--	--	--
3	CH ₃		 sm = endo prod = exo	oil	260.3	260	73.82	7.74	73.19	8.03

Preparation 4Bis(2-methoxy-5-bromophenyl)carbonate

5 Dissolved (8.26 ml, 160 mmol, 2.2 eq) bromine in 10 ml of CHCl_3 and then added it dropwise over 10 minutes to (20.0 g, 72.9 mmol, 1.0 eq) of bis(2-methoxy-phenyl)carbonate in 60 ml of CHCl_3 at room temperature. Stirred for 60 minutes at room temperature, then filtered the reaction mixture, washing the precipitate three times with CHCl_3 and once with hexane. The precipitate was recrystallized from CHCl_3 to yield 20.7 g, 66% yield, of bis(2-methoxy-5-bromophenyl)carbonate as white prisms.

Preparation 55-Bromoguaiacol


15 A suspension of (20.7 g, 47.9 mmol, 1.0 eq) bis(2-methoxy-5-bromophenyl)-carbonate in 250 ml methanol and 60 ml (120 mmol, 2.5 eq) of 2N NaOH was refluxed for 2 hours. The reaction mixture was cooled to room temperature, concentrated to a volume of ca 100 ml, and poured into 1 L of H_2O . The pH was adjusted to 2 using 1 N HCl. The acidic mixture was transferred to a separatory funnel, and extracted three times with ether. The ether extracts were combined and washed once with H_2O , once with brine, and then dried over anhydrous sodium sulfate. Filtration, concentration and drying afforded 19.0 g of a white solid, which was recrystallized from petroleum ether to yield 17.63 g, 91% yield, of white prisms.

Preparation 62-(5-Bromo-2-methoxyphenoxy)bicyclo[2.2.1]heptane





25 Neat diethylazodicarboxylate (1.4 ml, 8.87 mmol, 1.2 eq) was added to a 25°C solution of (1.50 g, 7.39 mmol, 1.0 eq) 5-bromoguaiacol, (2.13 g, 8.13 mmol, 1.1 eq) triphenylphosphine and (0.829 g, 7.39 mmol, 1.0 eq) of S(-)-endo-nor-borneol in 25 ml of anhydrous tetrahydrofuran. After stirring 18 hours at room temperature under N_2 , the reaction mixture was diluted with 350 ml of ether, washed twice with 1 N NaOH, once with H_2O , once with brine, and then dried over anhydrous Na_2SO_4 . Filtration, concentration and drying afforded a yellow oil which was triturated with ca 250 ml of 1:1 ether-hexane to remove triphenylphosphine oxide. The filtrate was concentrated in vacuo, and chromatographed on a silica gel column, eluting with 10% ethyl acetate-hexane, to afford 1.75 g, 80% yield, of a clear, colorless oil. Elemental Analysis: Calc'd for $\text{C}_{14}\text{H}_{17}\text{O}_2\text{Br}$: Calc'd: C, 56.57; H, 5.77%. Found: C, 56.68; H, 5.73%.


Preparations 7-13

Reaction of 5-bromoguaiacol with the requisite alcohol of the formula $\text{R}^2\text{-OH}$, analogous to the procedure of Preparation 11, afforded the following compounds:



Prep.#	R ²	M.P. °C	M.W.	Mass Spec (M+)	Analysis			
					Calculated (%)		Found (%)	
					C	H	C	H
7	 endo = sm exo = prod	oil	297.3	298	--	--	--	--
8	 Ph	oil	349.3	350	--	--	--	--

Prep.#	R ²	M.P. °C	M.W.	Mass Spec (M+)	Analysis			
					Calculated (%)		Found (%)	
					C	H	C	H
9	 R(+) = sm S(+) = prod	oil	297.2	298	56.57	5.77	56.74	5.72
10	 R(-) = sm S(+) = prod	oil	349.29	349.2	61.89	6.09	61.18	6.10
11	 S(+) = sm R(+) = prod	oil	349.29	349.2	61.89	6.09	59.77	5.66
12		oil	271.17	271.1	53.16	5.58	53.41	5.62

Prep.#	R ²	M.P. °C	M.W.	Mass Spec (M ⁺)	Analysis			
					Calculated (%)		Found (%)	
					C	H	C	H
13		oil	335.26	--	--	--	--	--

*sm = starting material
prod = product

Preparation 143-Cyclopentyl-4-methoxybenzoic acid

To a stirred suspension of (5.0 g, 27 mmol, 1.0 eq) methyl vanillate, (2.5 ml, 27 mmol, 1.0 eq) cyclopentanol, and (7.4 g, 28 mmol, 1.05 eq) triphenylphosphine in 40 ml of anhydrous tetrahydrofuran was added (4.7 ml, 29.7 mmol, 1.1 eq) of diethylazodicarboxylate. The reaction mixture was stirred 18 hours at room temperature, concentrated *in vacuo*, and flash chromatographed on a silica gel column, eluting with 20% ethyl acetate/hexane, to yield 7.0 g, > 100%, of an oil, methyl-3-methoxy-4-cyclopentyl-oxybenzoate.

A mixture of (7.0 g, 27 mmol, 1.0 eq) methyl-3-methoxy-4-cyclopentyl-oxy benzoate, 8 ml (42 mmol, 1.5 eq) 5N NaOH and 40 ml MeOH was refluxed for 3 hours. The mixture was concentrated to *ca* 20 ml, poured into 400 ml H₂O (pH 10) and washed twice with ether. The aqueous layer was acidified to pH 1 and extracted twice with ether. The ether extracts were combined, washed once with H₂O, once with brine, dried over MgSO₄ and then concentrated to yield 6 g of a white solid. Recrystallization from ether-hexane yielded 5.60 g, 83%, of white crystals. Elemental Analysis: Calcd. for C₁₃H₁₆O₄: Calcd: C, 66.09; H, 6.83. Found: C, 66.20; H, 6.64.

Preparation 142-Butyl-3-(4-hydroxyphenyl)benzimidazole

A mixture of (8.0 g, 51 mmol, 1.0 eq) 1-chloro-2-nitrobenzene and (5.54 g, 51 mmol, 1.0 eq) 4-aminophenol in 40 ml of dry dimethylsulfoxide was heated to reflux for 18 hours. The reaction mixture was cooled, poured into 400 ml of 0.1N HCl and 400 ml ethyl acetate, stirred, and filtered through celite. The filtrate layers were separated, and the aqueous layer was extracted with ethyl acetate. The ethyl acetate extracts were combined, washed twice with H₂O, once with brine, dried over MgSO₄, and concentrated to give 8 g of a dark oil. Silica gel chromatography eluting with 20% ethyl acetate/hexane gave 1.63 g, 14%, of a red solid.

A mixture of (1.6 g, 6.89 mmol, 1.0 eq) 4-N-(2-nitrophenyl)amino phenol and 800 mg of 10% Pd/C in 100 ml ethyl acetate was placed on a Parr hydrogenation apparatus and shaken under 50 psi H₂ for 3 hours. The mixture was filtered through celite, concentrated *in vacuo*, and chromatographed on a silica gel column eluting with 50% ethyl acetate/hexane to give 1.3 g, 94%, of an orange-yellow solid.


A mixture of (600 mg, 3.00 mmol, 1.0 eq) 4-N-(2-aminophenyl)amino phenol and 10 ml valeric anhydride was heated to reflux for 18 hours. The mixture was taken up in 50 ml of methanol, basified with 2N NaOH to pH 10, and stirred 1 hour at room temperature. The reaction mixture was then neutralized and extracted twice with ethyl acetate. The ethyl acetate extracts were combined, washed twice with H₂O, once with brine, dried over MgSO₄ and concentrated to give 1 g of an oil. Silica gel chromatography eluting with 2½% CH₃OH-CH₂Cl₂ gave 124 mg, 16%, solid. M.P.: 192-194°C.

Preparation 154-[(5-Bromo-2-methoxy)phenoxy]butanoic acid ethyl ester

A mixture of 15.0 g (0.0740 mol) of 2-methoxy-4-bromophenol, 17.4 g (0.0890 mol) of ethyl 4-bromobutyrate, 20.5 g (0.148 mol) of K₂CO₃, and 200 ml of DMF was stirred at about 80°C was continued for about 16 h. The combined ether extracts were washed with brine (1 x 300 ml), dried (MgSO₄), and evaporated to give 26.0 g of an orange oil. Purification by flash chromatography using an ethyl acetate-hexane (1:4) eluant gave 19.7 g (84%) of the title compound as a clear oil (R_f 0.5 EtOAc-hexane, 3:7). ¹H-NMR (CDCl₃) δ 1.25 (3H, t, J=7), 2.09-2.18 (2H, m), 2.51 (2H, t, J=7), 3.82 (3H, s), 4.03 (2H, t, J=7), 4.13 (2H, q, J=7), 6.72 (1H, d, J=8), 6.97-7.08 (2H, m).

Claims

1. The use of a compound selected from the group consisting of compounds of the formula (I)



(I)

the racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof wherein

R¹ is selected from the group consisting of methyl, ethyl, difluoromethyl and trifluoromethyl;

R² is selected from the group consisting of (C₁-C₆)alkyl, alkoxyalkyl having 3 to 7 carbons in the alkoxy portion and 2 to 4 carbons in the alkyl portion, phenoxyalkyl having 2 to 6 carbons in the alkyl portion, (C₃-C₇)cycloalkyl, (C₆-C₉) polycycloalkyl, phenylalkyl having 1 to 8 carbons in the alkyl portion, Phenylaminoalkyl having 2 to 6 carbons in the alkyl portion and the amino may be optionally substituted with (C₁-C₄) alkyl and indanyl,

where the alkyl portion of said alkyl, phenoxyalkyl, cycloalkyl, polycycloalkyl, phenylalkyl and indanyl may optionally be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,

and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄) alkyl, (C₁-C₄)alkoxy or halogen;

A and B are independently selected from the group consisting of a covalent bond, optionally substituted (C₁-C₅) alkylene, optionally substituted (C₂-C₅)alkenyl and optionally substituted phenylene,

where said optionally substituted alkylene may be monosubstituted and each substituent is selected from the group consisting of oxo, (C₁-C₄)alkoxy, CO₂R⁶ and hydroxy,


said optionally substituted alkenyl may be monosubstituted with (C₁-C₄)alkoxy or CO₂R⁶, and

said optionally substituted phenylene may be monosubstituted with (C₁-C₄)alkoxy, CO₂R⁶ or hydroxy,

wherein R⁶ is hydrogen or (C₁-C₄)alkyl;

Y is selected from the group consisting of a covalent bond, O, NR⁶ and S wherein R⁶ is as defined above;

Z is selected from the group consisting of



where Q¹, Q², Q³, and Q⁴ are independently N, CH or, when also bonded to B, C and provided that at least two of Q¹, Q², Q³, and Q⁴ are not N;

X is selected from the group consisting of NR⁴ and S;

e is an integer from 1 to 3;

g is an integer from 1 to 4;

j is an integer from 1 to 5;

each R³ is independently selected from the group consisting of hydrogen, halogen, CF₃, (C₁-C₆)alkyl, CH(R⁷) CO₂R⁴, (C₁-C₆)alkoxy, CO₂R⁴, CONR⁴R⁵, CONHOH, CH₂NR⁴R⁵, NR⁴R⁵, nitro, hydroxy, CN, SO₃H, phenylalkyl

having 1 to 4 carbons in the alkyl portion, $\text{SO}_2\text{NR}^4\text{R}^5$, $\text{N}(\text{SO}_2\text{R}^8)_2$ and NHSO_2R^8 .

where R^4 for each occurrence is independently selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$, phenyl optionally substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$ or halogen, $\text{CH}(\text{R}^7)\text{CO}_2\text{R}^6$, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, phenylalkyl having 1 to 4 carbons in the alkyl portion and dialkylaminoalkyl having a total of 5 carbons in the dialkylamino portion and having 2 to 5 carbons in the alkyl portion where R^6 is as defined above,

R^5 for each occurrence is independently selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, phenylalkyl having 1 to 4 carbons in the alkyl portion, phenyl, pyridyl, pyrimidyl, thiazolyl and oxazolyl,

or R^4 and R^5 are taken together with the nitrogen to which they are attached and form an optionally substituted saturated or unsaturated 5- or 6-membered ring, a saturated or unsaturated 6-membered heterocyclic ring containing two heteroatoms, or a quinoline ring optionally substituted with fluoro,

where said optionally substituted saturated or unsaturated 5- or 6-membered ring may be mono- or di-substituted and each substituent is independently selected from the group consisting of alkyl having 1 to 4 carbons, CO_2R^7 wherein R^7 is as defined below, CONH_2 , $\text{CON}(\text{CH}_3)_2$, oxo, hydroxy, NH_2 and $\text{N}(\text{CH}_3)_2$, and said saturated or unsaturated 6-membered heterocyclic ring containing two heteroatoms has the second heteroatom selected from the group consisting of O, S, NH, NCH_3 , NCOCH_3 and NCH_2Ph ;


R^7 for each occurrence is independently selected from the group consisting of hydrogen and $(\text{C}_1\text{-C}_4)\text{alkyl}$;

and R^8 is selected from the group consisting of $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, phenyl and phenylalkyl having 1 to 4 carbons in the alkyl portion;


with the proviso that:

when R^1 is methyl or ethyl; R^2 is $(\text{C}_7\text{-C}_9)\text{polycycloalkyl}$ or indanyl; A, B and Y are covalent bonds; X is N; and R^3 is hydrogen;

then Z is not




when the compound of formula I is



wherein X is CH or N and R^2 is as defined above for formula I, the CO_2H can only be in the para position relative to the bond to the catechol moiety;

when the compound of formula I is



wherein X is CH or N and R^2 and R^5 are as defined above for formula I, the amide can only be in the para or meta position; and the compound of formula I cannot be *trans*-1-[4-[2-[3(cyclopentyloxy)-4-methoxy-phenyl]-ethenyl]phenyl]-2-methyl-1H-imidazo[4,5-c]-pyridine, for the manufacture of a medicament for inhibiting production of TNF (tumour erosion factor).


2. A use according to claim 1 wherein R^1 is methyl or difluoromethyl; R^2 is $(\text{C}_3\text{-C}_7)\text{cycloalkyl}$, $(\text{C}_6\text{-C}_9)\text{polycycloalkyl}$, phenylalkyl, phenoxyalkyl or indanyl,

where the alkyl portion of said alkyl, cycloalkyl, polycycloalkyl, phenylalkyl, phenoxyalkyl and indanyl may

optionally be substituted with one or more fluorine atoms, -OH or (C₁-C₄)alkoxy,


and the aryl portion of said phenylalkyl, phenoxyalkyl and indanyl may optionally be substituted with (C₁-C₄) alkyl, (C₁-C₄)alkoxy or halogen.

3. A use according to claim 2 wherein A and B are independently selected from the group consisting of a covalent bond, (C₁-C₅)alkylene, (C₂-C₅)alkenyl and phenylene; and Y is a covalent bond or O.
4. A use according to claim 3 wherein A is a covalent bond, methylene or cis-ethenyl; B is a covalent bond or phenylene and Z is selected from the group consisting of




wherein j is 1 or 2; Q⁴ is CH or N and Q² is CH or N.


5. A use according to claim 4 wherein R¹ is methyl; R² is cyclopentyl, norbornyl, indanyl, 1-phenylbut-3-yl, 1-phenoxyeth-2-yl, 1-phenylhex-5-yl or 1-phenylpent-4-yl; R³ is (C₁-C₄)alkyl, CO₂H, CONH₂, nitro, NHSO₂Me, CF₃ or hydrogen; and e is 1.
6. A use according to claim 5 wherein Z is selected from the group consisting of




wherein R³ is H, CO₂H or CONH₂.



wherein R³ is (C₁-C₆)alkyl,



wherein R³ is H, CO₂H or CONH₂, and




wherein R³ is (C₁-C₆)alkyl, H, CO₂H, CONH₂, CF₃, NO₂ or NHSO₂Me.

7. A use according to any one of the preceding claims, which is for the manufacture of a medicament for treating or alleviating an inflammatory condition or disease, sepsis, septic shock, tuberculosis, multiple sclerosis and other autoimmune diseases, graft versus host disease or cachexia associated with AIDS or cancer in a mammal.

8. A use according to claim 7 wherein the inflammatory disease or condition is rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis or inflammatory bowel disease.


9. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a tumor necrosis factor inhibiting amount of a compound selected from the group consisting of compounds of the formula (I)



(I) the racemic-diastereomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts thereof as defined in any one of claims 1 to 6, together with instructions for the use thereof for the treatment or alleviation of a condition as defined in claim 7 or 8.

10. Commercial package containing a compound of the formula (I), racemic- diastereomeric mixture or optical isomer or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 6 in a form suitable for oral or parenteral administration, together with or bearing instructions for the use thereof in treating or alleviating a condition as defined in claim 7 or 8.

THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 706 795 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
17.12.1997 Bulletin 1997/51

(43) Date of publication A2:
17.04.1996 Bulletin 1996/16

(21) Application number: 95306159.5

(22) Date of filing: 04.09.1995

(51) Int Cl.⁶: **A61K 31/44**, A61K 31/50,
A61K 31/505, A61K 31/165,
A61K 31/415, A61K 31/19,
A61K 31/09, A61K 31/18

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

(30) Priority **21.09.1994 US 310171**

(71) Applicant **PFIZER INC.**
New York, N.Y. 10017 (US)

(72) Inventors:
• **Cohan, Victoria L.**
Groton, Connecticut 06340 (US)
• **Duplantier, Allen J.**
Ledyard, Connecticut 06339 (US)

(74) Representative: **Wood, David John et al**
PFIZER LIMITED,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Catechol diether compounds as inhibitors of TNF release**

(57) This invention relates to the use of catechol diether compounds for the manufacture of a medicament for use as an inhibitor of tumor necrosis factor (TNF). The catechol diether compounds are useful as inhibitors of TNF per se and in the treatment or alleviation of inflammatory conditions or disease, including but not limited to

ited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, dermatitis and inflammatory bowel disease, sepsis, septic shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer.

EP 0 706 795 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 95 30 6159
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (In Cl.6)
E	WO 95 27692 A (SMITHKLINE BEECHAM CORPORATION) 19 October 1995 * the whole document *	1-10	A61K31/44 A61K31/50 A61K31/505 A61K31/165 A61K31/415 A61K31/19 A61K31/09 A61K31/18
P,X	EP 0 636 369 A (PFIZER INC.) 1 February 1995 * the whole document *	1-10	
D,Y	WO 94 12461 A (PFIZER INC.) 9 June 1994 * the whole document *	1-10	
Y	TURNER CR ET AL: "Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition." CIRC SHOCK, MAR 1993, 39 (3) P237-45, UNITED STATES, XP002042653 * abstract * * description *	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		6 October 1997	Mair, J
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>			

EPO FORM 1503 03.82 (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 95 30 6159

Claim(s) searched completely:
0

Claim(s) searched incompletely:
1-10

Reason for the limitation of the search:

In view of the large number of compounds which are theoretically defined by the formula of claim 1, the search had to be restricted on economic grounds to the exemplified compounds and the general concept of the application.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 95 30 6159

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,Y	<p>PRAKHABAR, U. ET AL: "Characterization of cAMP-dependent inhibition of LPS-induced TNF-alpha production by Rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor"</p> <p>INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 16, no. 10, October 1994, pages 805-816, XP002042654 * the whole document *</p> <p>---</p>	1-10	
Y	<p>BARNETTE, M.S. ET AL: "SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor, suppresses activities of several immune and inflammatory cells"</p> <p>AMERICAN JOURNAL OF RESPIRATORY CRITICAL CARE MEDICINE, vol. 149, 1994, page a209 XP002042655 * the whole document *</p> <p>-----</p>	1-10	<p>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</p>

EPO FORM 1502 (3.82) (P04C16)